{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:59:49Z","timestamp":1782795589353,"version":"3.54.5"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>This trial assessed the efficacy and safety of the possibility of varying the daily injection time of once\u2010daily, long\u2010acting basal insulin degludec (<jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg) in Japanese patients with type 2 diabetes inadequately controlled with insulin glargine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This was a 26\u2010week, multicenter, open\u2010label, randomized, treat\u2010to\u2010target trial, with a 2 \u00d7 2 factorial design comparing <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg flexible (allowing dosing \u00b18 h from an agreed dosing time) with <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg fixed dosing (at the same time each day). It was carried out in 458 adult patients who were inadequately controlled on insulin glargine with or without oral antidiabetic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The majority of doses were taken within 2 h of the agreed dosing time, showing a high level of adherence among Japanese patients. After 26 weeks, <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg flexible was non\u2010inferior to <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg fixed with respect to change in glycated hemoglobin from baseline, estimated treatment difference 0.08% points (95% confidence interval \u22120.05; 0.22). Fasting plasma glucose decreased to a similar level with <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg flexible and <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg fixed, estimated treatment difference \u22120.18 mmol\/L (95% confidence interval \u22120.48; 0.12). The rates of confirmed and nocturnal confirmed hypoglycemia were numerically, but not significantly, higher with <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg flexible vs <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg fixed dosing. The rates of adverse events with <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg flexible and <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg fixed dosing were similar.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results showed the efficacy and safety of allowing patients to vary the time they dosed <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg, when necessary, in Japanese patients with type 2 diabetes. Dosing of <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>eg at a time convenient to the patient was non\u2010inferior, with respect to glycated hemoglobin, to dosing at the same time each day.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.12502","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T05:06:42Z","timestamp":1456376802000},"page":"711-717","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of once\u2010daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26\u2010week, treat\u2010to\u2010target trial"],"prefix":"10.1111","volume":"7","author":[{"given":"Takashi","family":"Kadowaki","sequence":"first","affiliation":[{"name":"Department of Metabolic Diseases Graduate School of Medicine and Faculty of Medicine The University of Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Jinnouchi","sequence":"additional","affiliation":[{"name":"Iryo Houjin Shadan Jinnouchikai Jinnouchi Hospital Kumamoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Kawasaki Medical School Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene L","family":"Hersl\u00f8v","sequence":"additional","affiliation":[{"name":"Medical &amp; Science Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Hyllested\u2010Winge","sequence":"additional","affiliation":[{"name":"Medical &amp; Scientific Affairs Novo Nordisk Pharma Ltd Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Iryo Houjin Shadan Kowakai Heiwadai Hospital Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3460-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01395.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03605.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.855187"},{"issue":"1","key":"e_1_2_7_7_1","first-page":"S397","article-title":"GAPP2: Global survey finds that a quarter of Japanese type 2 diabetes downplay insulin non\u2010adherence to their healthcare professional","volume":"55","author":"Atsumi Y","year":"2012","journal-title":"Diabetologia"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.743458"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm031"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/193229680800200209"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12399"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01638.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0076-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12102"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3249"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1668"},{"key":"e_1_2_7_18_1","unstructured":"World Medical Association.Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Last amended by the59th WMA Assembly Seoul October 2008."},{"key":"e_1_2_7_19_1","unstructured":"International Conference of Harmonisation.ICH Harmonised Tripartite Guideline. Good Clinical Practice 01 May 1996."},{"key":"e_1_2_7_20_1","unstructured":"Novo Nordisk A\/S. Last updated 2015.Tresiba (insulin degludec) label Japan. Available at:https:\/\/www.pmda.go.jp\/index.html. Accessed 26 August 2015."}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.12502","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12502","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.12502","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.12502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:21:25Z","timestamp":1696249285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.12502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1111\/jdi.12502"],"URL":"https:\/\/doi.org\/10.1111\/jdi.12502","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}